Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS -- Ignore unavailable to you. Want to Upgrade?

To: FZupan who wrote (10256)	5/11/1999 12:46:00 PM
From: * Thumper *	Respond to of 13776

Anybody know why IVIG is moving today on little volume??? <eom> :-)

To: FZupan who wrote (10256)	5/11/1999 12:46:00 PM
From: ErnestPoe	Read Replies (1) \| Respond to of 13776

PRXX check this out!! STOCKWATCH: Praxis Pharmaceuticals COULD PRAXIS BE THE NEXT MERCK OR JOHNSON & JOHNSON? DRUG RESEARCH PROGRAM HOLDS THE KEY WORLD CLASS PHARMACEUTICAL RESEARCH COMPANY IN FINAL NEGOTIATIONS FOR MAJOR FINANCING AND JOINT VENTURE SAN DIEGO, CALIFORNIA, May 10, 1999 - Investment analysts, stockbrokers, and major investors throughout North America are expected to participate in a telephone-conference tomorrow with noted medical researchers, Dr. William Cowden and Dr. Brett Charlton, who are also the principals of Praxis Pharmaceuticals Inc., to hear news of the company's most recent corporate and research developments. The doctors are in San Diego to attend a medical conference. Praxis Pharmaceuticals has under development a number of therapeutic products based on carborhydrate chemistry. They are for use in the treatment of diabetes, arthritis, multiple sclerosis, psoriasis, surgical adhesions, ocular inflammation and to treat skin-aging(wrinkles). Praxis also has a patent for a pharmaceutical that has been shown in laboratory tests to prevent the rejection of organ transplants. Carbohydrate chemistry is the chemistry associated with sugar molecules. The knowledge that human proteins and cells are coated with sugar allows Praxis scientists to use their expertise to facilitate unique proprietary treatments for various medical conditions. Dr. Cowden, CEO of Praxis, is one of the few scientists in the world who has worked exclusively in the therapeutic carbohydrate field for over ten years. He is the inventor of seven patents in this field, which have been licensed by pharmaceutical firms including one of the world's largest Johnson and Johnson. A number of authorities feel this branch of medical science will be the next major breakthrough in the treatment of certain medical conditions. While the Praxis corporate offices are in Vancouver, Canada, laboratory facilities are at the world-famous John Curtin School of Medical Research in Canberra, Australia, where four of that school's faculty have received the Nobel Prize in medicine. Praxis is currently in negotiations on two fronts - one involves a major financing by an international investment group and the other is a joint-venture with a U.S. company to market two of its over-the-counter compounds. One of these compounds is for the treatment of facial wrinkles, which will be an inexpensive replacement for other forms of facial enhancements including surgical face lifts and collagen needle injections. The other compound is for certain forms of arthritis. According to the Arthritis Society, about 37.9 million people, or 15% of the American population, have some form of arthritic condition. Potential market for products currently in the Praxis pipeline is estimated at $80-billion in the United States alone. So far research and development costs for the medical technology Praxis has under license exceeds $9-million. FOR FUTHER INFORMATION CALL: Stockbroker Relations at 1-800-546-7950 or Praxis Corporate Offices at 1-604-646-5614 THE PRAXIS WEB SITE IS: praxis-pharmaceuticals.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Information in this document contains forward-looking statements. All such forward statements are, by necessity, only estimates of future results and actual results achieved by Praxis may differ materially from these statements due to a number of factors. Praxis assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements.